Tong-Shuang Li

This inventor holds 9 USPTO granted patents and 1 published patent application, plus 2 CIPO patents and 5 EPO patents. Top assignees: Alectos Therapeutics Inc., Merck Sharp + Dohme Corp., Genzyme Corporation. Active years: 2009-2017.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Tong-Shuang Li. Retrieved from https://idiyas.com/inventor/tong-shuang-li

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 9 (Patent Applications = 1)

% Patents Active = 11.1

CIPO Patents = 2

EPO Patents = 5 (Patent Applications = 5)

Average Co-Inventor Count = 7.2

ph-index = 3

Forward Citations = 48(Granted Patents)

Location History:

Langley, CA (2009 - 2015)
Burnaby, CA (2015 - 2017)

Company Filing History:

4 out of 19

Alectos Therapeutics Inc.

patents

4 out of 2,405

Merck Sharp + Dohme Corp.

Simon Fraser University

patents

where one patent can have more than one assignee

Years Active: 2009-2017

Loading Chart...

9 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 9701693 - Selective glycosidase inhibitors and uses thereof (2017-07-11),

2. 9409924 - Selective glycosidase inhibitors and uses thereof (2016-08-09),

3. 9199949 - Selective glycosidase inhibitors and uses thereof (2015-12-01),

4. 9120781 - Selective glycosidase inhibitors and uses thereof (2015-09-01),

5. 8962664 - Selective glycosidase inhibitors and uses thereof (2015-02-24),

6. 8334310 - Selective glycosidase inhibitors and uses thereof (2012-12-18),

7. 7790747 - Chemokine receptor binding compounds (2010-09-07),

8. 7498346 - Chemokine receptor binding compounds (2009-03-03),

9. 7491735 - Chemokine receptor binding compounds (2009-02-17),

Title: Innovations of Tong-Shuang Li

Introduction

Tong-Shuang Li is a prominent inventor based in Langley, Canada. He has made significant contributions to the field of glycosidase inhibitors, holding a total of nine patents. His work focuses on developing compounds that can selectively inhibit glycosidases, which are crucial in various biological processes.

Latest Patents

Among his latest patents are two notable inventions related to selective glycosidase inhibitors. The first patent provides compounds for selectively inhibiting glycosidases, along with prodrugs of these compounds and pharmaceutical compositions that include them. This invention also outlines methods for treating diseases and disorders associated with the deficiency or overexpression of O-GlcNAcase, as well as the accumulation or deficiency of O-GlcNAc. The second patent similarly offers compounds with enhanced permeability for the selective inhibition of glycosidases, along with corresponding prodrugs and pharmaceutical compositions. This invention also addresses treatment methods for related diseases and disorders.

Career Highlights

Tong-Shuang Li has worked with notable companies in the pharmaceutical industry, including Merck Sharp & Dohme Corporation and Alectos Therapeutics Inc. His experience in these organizations has contributed to his expertise in drug development and innovation.

Collaborations

Some of his notable coworkers include Yuanxi Zhou and David Jaro Vocadlo. Their collaborations have likely played a role in advancing research and development in the field of glycosidase inhibitors.

Conclusion

Tong-Shuang Li's innovative work in the development of selective glycosidase inhibitors has the potential to impact the treatment of various diseases. His contributions to the field are significant and demonstrate the importance of continued research and innovation in pharmaceuticals.

Profile summary based on public USPTO records.